The in vitro capacity of DFAC, as established in the present study, warrants further investigation in pre-clinical tumor models to establish its performance as a theranostic probe for the treatment of head and neck cancers with potential applicability in other EGFR over-expressing tumor tissues. Here, EGFR is linked to head and neck cancer.